TFF Pharmaceuticals, Inc (TFFP) - Long-Term Debt to Capital Coefficient

TFF Pharmaceuticals (TFFP) utilizes a thin-film freezing method to convert liquid formulations into powder inhalers, as confirmed by this price trend chart. The company's revenues are based on long-term royalties from global pharma behemoths. Business success relies on licensing efficiency and production stability. The current metric stands at 0.00, while the pricing strategy is tied to the ownership of unique drug delivery patents.

The long-term debt-to-equity ratio determines the proportion of long-term liabilities within a company's overall equity financing structure. This metric allows an investor to assess the financial stability and the extent of the issuer's dependence on external borrowings. By analyzing the long-term debt structure relative to equity, one can identify the balance between bankruptcy risks and expansion rates. For TFF Pharmaceuticals (TFFP), this indicator is critical, as patents for inhalation powders generate stable royalties, reducing the need for loans.